

**A Six-hour Hemodialysis Without a Significant Increase in Dialysis Dose, as Judged by Kt/V, Can Reduce the Dosage of Erythropoietin**

**Department of Kidney Center, Kouzenkai-Maeda Hospital**

**Atsuhiko Maeda**

# Background

**Inadequate dialysis is a known risk factor for resistance to erythropoietin (EPO) therapy. ※1~5**

**There is no consensus about the relationship between hemodialysis (HD) time and EPO dosage.**

※1 Locatelli et al : Semin Nephrol 26 : 269-274 , 2006

※2 Movilli et al : J Nephrol 16 : 546 – 551 , 2003

※3 Movilli et al : Nephrol Dial Transplant 16 : 111 – 114 , 2001

※4 Gawade et al : Clin J Am Soc Nephrol 5 : 576 – 581 , 2010

※5 Katzarki et al : Nephrol Dial Transplant 14 : 369 – 375 , 1999

## **Methods ①**

**We conducted a cross-sectional study on a total of seventy-eight HD patients with diabetes.**

**Subjects were recruited from three outpatient HD facilities in Japan.**

**At one facility, dialysis time was six hours (n=38) and at the other two facilities the dialysis time was four hours (n=40).**

## **Methods ②**

**The patients that participated in the study were at least twenty years of age and had undergone maintenance HD three times a week for at least six months.**

**Patients who have had any blood loss, blood transfusions, hospitalizations, or infections occurring within six months preceding the study were excluded.**

## Results ①

	4-Hour HD	6-Hour HD	P-Value
Age (years)	65.5	67.2	0.48
Length of Treatment (years)	5.2	5.0	0.81
Male (%)	62.5	71.1	0.47
Hemoglobin (g/dL)	11.2	11.0	0.43
Ferritin (ng/mL)	179.8	172.0	0.84
EPO Dosage (U/week)	5375.0	3111.8	0.001

## Results ②

	4-Hour HD	6-Hour HD	P-Value
<b>Albumin</b> (g/dL)	<b>3.7</b>	<b>3.8</b>	<b>0.28</b>
<b>C-Reactive Protein</b> (mg/dL)	<b>0.4</b>	<b>0.4</b>	<b>0.57</b>
<b>Intact Parathyroid Hormone</b> (ng/mL)	<b>135.8</b>	<b>114.3</b>	<b>0.42</b>
<b>Quantity of Blood Flow</b> (mL/minute)	<b>194.9</b>	<b>188.4</b>	<b>0.23</b>
<b>Kt/V</b>	<b>1.4</b>	<b>1.5</b>	<b>0.36</b>
<b>Membrane Surface Area</b> (m <sup>2</sup> )	<b>1.6</b>	<b>1.1</b>	<b>0.001</b>

## Multiple Regression Analysis with Weekly EPO Dose as Dependent Variable

	Coefficient	Standard Error	T-Statistic	P-Value*
Age	24.4	32.4	0.8	0.45
Ferritin	3.4	2.0	1.7	0.10
Kt/V	2111.1	1630.1	1.3	0.20
C-Reactive Protein	447.2	549.3	0.8	0.42
Dialysis Time	1165.6	324.9	3.6	0.001

$R^2 = 0.25$  \* :  $P < 0.05$

## Summary ①

**There were statistically significant findings in the six-hour HD patients with lower dosage of EPO. (3111.8 versus 5375.0U/week).**

**There was not a statistically significant difference of  $Kt/V$  between the six-hour and the four-hour HD patients. (1.4 versus 1.5)**



## **Summary ②**

**The dialysis time was the only statistically significant factor in multiple regression analysis with EPO responsiveness.**

## Discussion ①

Several studies have reported a positive relationship between EPO responsiveness and Kt/V. ※1~4

But these studies did not investigate the association between dialysis time and EPO requirement.

※1 Movilli et al : Nephrol Dial Transplant 16 : 111 – 114 , 2001

※2 Movilli et al : J Nephrol 16 : 546 – 551 , 2003

※3 Gawade et al : Clin J Am Soc Nephrol 5 : 576 – 581 , 2010

※4 Katzarki et al : Nephrol Dial Transplant 14 : 369 – 375 , 1999

## **Discussion ②**

**We found that there are lower EPO requirements among six-hour HD patients without increasing Kt/V.**

**Thus, the dialysis time is a more important factor of EPO responsiveness than Kt/V.**

## **Discussion ③**

**We attribute the similar results in  $Kt/V$  between six-hour and four-hour HD patients to a significantly smaller membrane surface area in six-hour HD patients.**

**A six-hour HD facility aims for slow and long dialysis treatments, all the HD patients have undergone six-hour HD using a dialyzer with a small membrane surface area, and  $Kt/V$  is also not higher than the four-hour HD.**

## Discussion ④

Several studies have reported that a higher dosage of EPO increases the risk of death and cardiovascular events in HD patients. ※1~3

Long-hours HD is known to have a good survival prognosis, which is one factor of why there may be the lower EPO dosage.

※1 Zhang et al : Kidney Int 80: 663-669, 2011

※2 Zhang et al : Am J Kidney Dis 44: 866-876, 2004

※3 Santos et al : Hemodial Int 15:493-500, 2011

## **Limitation**

**This study is a cross-sectional analysis among subjects of HD patients with diabetes, which must be followed by a prospective randomized analysis among subjects comprising of all the HD patients.**

## **Conclusion**

**The dialysis time is a more important factor of EPO response than  $Kt/V$ .**





# Biography

November 18, 1974

Date of Birth

## WORK EXPERIENCE

April 2000

Medical Practitioner National Board Examination Certification

May 2000

Japanese Red Cross Fukuoka Hospital Intern for Internal Medicine

May 2001

Kyushu University Hospital Intern for Internal Medicine

May 2002

Japanese Red Cross Fukuoka Hospital Nephrologist

May 2003

Steel Memorial Yawata Hospital Nephrologist

May 2004

Saiseikai Yahata General Hospital Nephrologist

April 2007

Aso Iizuka Hospital Nephrologist


April 2012

Kouzenkai Maeda Hospital Nephrologist

# **Speciality**

- **Hemodialysis**
- **Continuous ambulatory peritoneal dialysis**
- **Renal transplantation**
- **Hypertension**
- **Diabetes mellitus**
- **Treatment of chronic kidney disease**
- **Treatment of acute kidney injury**

Imari city, Japan  
Population: 58,000



# Specify of affiliation



## KOUZENKAI-MAEDA HOSPITAL CAPACITY AND AMENITIES

Hospital Founded	Established in April 1916
Inpatients	129 Inpatient beds
Renal Failure Outpatients	900 Patients per month
Diabetic Outpatients	800 Patients per month
Hemodialysis Outpatients	160 Patients